Prostate ablation using HIFU — the role of patient preference information

A newly published review by staff of the Center for Devices and Radiological Health (CDRH at the U.S. Food & Drug Administration (FD) addresses the potential role for patient preference information (PPI) in determining patient perceptions of the “value” of high-intensity focused ultrasound (HIFU) and similar techniques in the management of prostate cancer. … READ MORE …

Comparative effectiveness of new treatments for early stage prostate cancer

As initially reported in The Gray Sheet, an advisory committee to the US Food and Drug Administration (FDA) has suggested that new forms of device-based treatment for organ-confined prostate cancer should have to demonstrate effectiveness and safety in randomized clinical trials compared to active surveillance. … READ MORE …